We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 639

To correct inventorship of a patent, go to the PTO, not the federal courts

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 30 2013

Faced with the question of whether a federal district court should change the inventors listed on the face of a patent, the Federal Circuit found

When can a design patent continuation applications claim priority to a parent?

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 30 2013

Addressing the issue of when and under what circumstances a design patent application can receive the benefit of the written description of its parent

USPTO adopts new professional conduct rules

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 30 2013

The U.S. Patent and Trademark Office (USPTO) recently released new rules for professional conduct that take effect on May 3, 2013. See 78 Fed. Reg

Infringement damages limited to U.S. sales and must not be speculative

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 30 2013

In a decision addressing several damages-related issues, the U.S. Court of Appeals for the Federal Circuit held that a patentee's damages award

Patent marking: an extrajudicial admission that the product is covered by the patent but not an estoppel

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 30 2013

Addressing for the first time whether marking a product with a patent number creates an estoppel preventing a later assertion that the product is not

IRS capitalized legal fees incurred by pharmaceutical company

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 15 2013

In a recently released Field Attorney Advice, the Internal Revenue Service (IRS) Office of Chief Counsel concluded that a pharmaceutical company must

Osteoporosis patents found invalid

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 15 2013

Two osteoporosis treatment patents have been found to be invalid following the ruling by the High Court of England and Wales in Hospira UK Ltd & Anor

A new front in the patent wars: CJEU asked for guidance on limits to injunctive relief

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • April 11 2013

The patent wars between large technology companies continue unabated. The Court of Justice of the European Union (CJEU) is set to provide guidance on

Six-month report card: post-issuance proceedings under the AIA

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 8 2013

Ob September 16, 2012, the U.S. Patent and Trademark Office (USPTO) implemented the provisions of the America Invents Act (AIA) to provide

Joint actors as it relates to method claim infringement

  • McDermott Will & Emery
  • -
  • USA
  • -
  • March 29 2013

Addressing infringement of a method claim by one or two actors, the U.S. Court of Appeals for the Federal Circuit vacated a district court's grant of